Announcement PDF RNS Number : 7687Z ValiRx PLC 21 October 2026 21 October 2026 ValiRx PLC ("ValiRx" or the "Company") Update on Ambrose Healthcare shareholding London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the movement in the Company's share price on 20 October 2026 following the announcement by Ambrose Healthcare Ltd ("Ambrose"), a private UK specialist pharmaceutical company, regarding its acquisition of AM-Pharma for up to €161 million. On 20 June 2025, ValiRx announced that its 54.14% owned subsidiary, ValiSeek Ltd ("ValiSeek"), a joint venture alongside Tangent Reprofiling, had entered into an intellectual property licence agreement with Ambrose in relation to VAL401. Under the agreement, ValiSeek received 576,000 ordinary shares in Ambrose and is entitled to clinical and commercial milestone payments of up to £16 million, together with royalties. In addition, ValiSeek received 75,000 ordinary shares in Ambrose in connection with the original option agreement. These shareholdings represents approximately 5.55% of Ambrose's issued share capital. Mark Eccleston, CEO of ValiRx commented: "As the third largest shareholder in Ambrose, we're delighted to see the acquisition of this additional clinical stage asset with established positive safety in almost 700 patients. The asset, which has had over $250M invested into sepsis-associated kidney injury including a Phase 3 trial that ultimately gave disappointing results, now has demonstrated dose-dependent effect on disease biomarkers in a Phase 1b study in adult HPP patients and has received Orphan Drug Designation for HPP from both the FDA and the EMA, with an agreed development plan built around a single pivotal study giving the programme a new lease of life with an established early clinical package. The acquisition also gives Ambrose an EU regulatory, quality and scientific infrastructure as a strong base for their pipeline which includes ValiSeek's VAL401 asset. Given the previous big pharma interest in the asset and accelerated clinical pathway via the orphan disease route we think this could be a fast tracked route to a significant value inflection for Ambrose and thus ValiRx through its shareholding." The Directors of the Company take responsibility for this announcement. *** ENDS *** Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3 For more information, please contact: Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub https://valirx.com/link/P7NqJr ValiRx plc Dr Mark Eccleston, CEO Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti Tel: +44 (0) 20 7213 0880 Shard Capital Partners LLP (Sole Broker) Damon Heath Tel: +44 (0) 20 4530 6926 V Formation (Public Relations) Jocelyn Braithwaite +44 (0) 115 646 5491 www.vformation.co.uk jocelyn@vformation.co.uk Subscribe to our news alert service: https://valirx.com/s/f298d1 Notes for Editors About ValiRx ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives. ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development. Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets. ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance. Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL. For further information, visit: www.valirx.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCURRRRNAURUUA